ClinicalTrials.gg
Active, not recruitingNCT07065773Updated Feb 4, 2026

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

A Phase 2 interventional study of Trichostatin A in Onychomycosis of Toenail, sponsored by Vanda Pharmaceuticals. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Vanda Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.

Planned enrollment
37th of 75
50 · median 50
Started
2025
the only one that year
Phase 2
23 of 77
1 open now
Registered
75th of 77
by date

Among the 77 studies in Onychomycosis with a site in United States, this one is the 37th largest by planned enrollment of the 75 interventional ones that give a count, is the only one that started in 2025, is one of 23 in phase 2, and was the 75th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Onychomycosis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of topically administered VTR-297 solution. The efficacy objectives of the study will be assessed using fungal culture testing, Neutral Red Staining (NRS) microscopy examination, and KOH microscopy examination after 4 weeks of treatment with VTR-297.

03

Conditions studied

  • Onychomycosis of Toenail

Browse trials for

Keywords

  • Onychomycosis
  • Onychomycosis of Toenail
  • Trichophyton rubrum
  • Trichophyton mentagrophytes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness to provide signed and dated written voluntary .
  • Adults with diagnosis of mild-to-severe DLSO/DSO affecting at least one great toenail.
  • Positive microscopic examination with KOH for dermatophyte hyphae.
  • Positive dermatophyte culture or mixed dermatophyte/Candida culture.

Exclusion criteria

Exclusion Criteria:

  • Presence of other toenail infection.
  • Any disease or condition that may interfere with the evaluation including other conditions that affect the toenails or significant active tinea pedis.
  • History of other significant chronic fungal disease, psoriasis, lichen planus or use of drug medications for those indications 6 months prior to screening and during the study.
  • Participation in a previous clinical trial 3 months prior to screening or participation in a research study concurrent with this study.
  • Current or planned pregnancy during the trial period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Trichostatin A

    Drug: Trichostatin A

Interventions

  • DrugTrichostatin A

    Topical Study Drug

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.

    Time frame: 24 weeks

07

Study locations

5 sites
  • Vanda Investigational Site
    Fremont, California 94538, United States
  • Vanda Investigational Site
    Denver, Colorado 80210, United States
  • Vanda Investigational Site
    New Brighton, Minnesota 55112, United States
  • Vanda Investigational Site
    Pflugerville, Texas 78660, United States
  • Vanda Investigational Site
    Forest, Virginia 24551, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 16 months after the start.

Of 16 phase 2 interventional studies under Onychomycosis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 22. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jul 15, 2025
StartActual
May 5, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065773
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
May 5, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 4, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion